Aditxt, Inc.

ADTX Healthcare Biotechnology

Aditxt, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3,200.00, down 97.6% from fiscal 2024. In the quarter to March 2026, revenue grew 1,120.0%, EPS grew 99.6% and free cash flow grew 60.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.00 0.00 NaN
Market cap
$4.4M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
−22.29
Beneish M
n/a
Dividend safety
n/a

A Cash Flow Statement is a financial report that details the cash inflows and outflows of a company over a specific period. It is divided into three sections: operating activities, investing activities, and financing activities. This statement helps assess the company’s liquidity, solvency, and overall financial health. By tracking cash movements, it provides insights into the company's ability to generate cash to fund operations, pay debts, and invest in growth. Businesses and investors use it to evaluate the sustainability of a company's cash flow and its financial stability.

Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Net Income
0.00 (5.69) (5.83) (9.15) (46.37) (27.65) (32.39) (35.02) (42.79)
Operating Cash Flow
— (0.39) (0.46) (7.22) (22.28) (22.39) (19.20) (16.76) (25.69)
Investing cash flow
— — 0.00 (0.17) (16.31) (0.24) (0.01) (5.00) (2.44)
Financing cash flow
0.03 0.48 0.35 17.89 35.95 17.53 16.55 22.50 30.49
Ending Cash
— — 0.00 10.50 7.87 2.77 0.10 0.83 3.20
Other line items

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated 2 Oct 2026